EGFR and lung carcinoma: In contrast, classical lung cancer‐related pathways, including the JAK‐STAT signaling pathway, PI3K‐Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, NF‐kappa B signaling pathway, and MAPK signaling pathway, were significantly activated (Figure 4C; and Table S3, Supporting Information).